| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1007/S00520-017-3854-X |
| P8608 | Fatcat ID | release_vdr23m6kwrbp3ah235ktrljkne |
| P932 | PMC publication ID | 5827957 |
| P698 | PubMed publication ID | 28939926 |
| P2093 | author name string | Gary H Lyman | |
| Jeffrey Crawford | |||
| David C Dale | |||
| Kim Allcott | |||
| Maureen Reiner | |||
| Zandra Klippel | |||
| Phuong Khanh Morrow | |||
| Ellen Fan | |||
| Timothy Osslund | |||
| P2860 | cites work | The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy | Q87072742 |
| Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients | Q24198118 | ||
| Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies | Q27011514 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia | Q31030133 | ||
| Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer | Q33332252 | ||
| Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry | Q33346293 | ||
| Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma | Q33364972 | ||
| Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. | Q33498419 | ||
| A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). | Q33502338 | ||
| A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. | Q33503445 | ||
| Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management | Q33975071 | ||
| A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. | Q33998299 | ||
| Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis | Q34029496 | ||
| Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor | Q34192924 | ||
| Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study | Q34521035 | ||
| A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group | Q34743741 | ||
| Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia | Q35308552 | ||
| Meta-analysis in clinical trials revisited | Q36264762 | ||
| Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia | Q36897773 | ||
| XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy | Q37067591 | ||
| Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma | Q37708854 | ||
| A review of relative dose intensity and survival in patients with metastatic solid tumors | Q38280411 | ||
| Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice | Q40425420 | ||
| Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel | Q40635520 | ||
| Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia | Q40649348 | ||
| Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation | Q40689549 | ||
| Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial | Q40695971 | ||
| Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies | Q40697302 | ||
| Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy | Q40725458 | ||
| Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer | Q40746556 | ||
| Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices | Q41136283 | ||
| SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization | Q43462115 | ||
| CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial | Q44280913 | ||
| CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma | Q44547430 | ||
| Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide | Q44583967 | ||
| Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices | Q44691615 | ||
| Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques | Q45242100 | ||
| Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. | Q45964464 | ||
| Update on the management of neutropenia | Q48596810 | ||
| Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial | Q51549878 | ||
| Impact of primary prophylaxis on febrile neutropenia within community practices in the US | Q58310873 | ||
| Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans | Q71249390 | ||
| Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers | Q71654501 | ||
| Pulmonary complications of acute leukemia | Q72852570 | ||
| Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma | Q73374103 | ||
| Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working | Q74195504 | ||
| A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children | Q80937625 | ||
| Severe neutropenia in children: a single institutional experience | Q80971887 | ||
| Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim | Q85886227 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 7-20 | |
| P577 | publication date | 2017-09-22 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | A systematic literature review of the efficacy, effectiveness, and safety of filgrastim | |
| P478 | volume | 26 |
| Q92281981 | Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score |
| Q90306130 | Differential role of r-met-hu G-CSF on male reproductive function and development in prepubertal domestic mammals |
| Q58107666 | G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey |
| Q98293270 | Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials |
| Q101121020 | IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice |
| Q92861017 | Neutrophils as emerging therapeutic targets |
| Q90217905 | Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia |
Search more.